corona
viru
diseas
pandem
caus
massiv
global
public
health
havoc
recent
publish
clinic
trial
show
conflict
data
use
chloroquinehydroxychloroquin
studi
meticul
evalu
variou
dosag
chloroquin
hydroxychloroquin
util
clinic
trial
regist
chines
us
clinic
trial
registri
treatment
pneumonia
caus
moreov
result
publish
clinic
trial
vitro
studi
use
chloroquin
hydroxychloroquin
relev
diseas
discuss
save
live
prevent
rapid
viral
transmiss
chloroquin
phosphat
old
drug
use
treatment
malaria
caus
plasmodium
speci
chloroquin
phosphat
also
replac
anoth
member
famili
hydroxychloroquin
activ
compound
chloroquin
constitut
chloroquin
phosphat
hydroxychloroquin
respect
mechan
action
chloroquin
hydroxychloroquin
studi
sarscov
studi
use
vero
cell
found
treatment
cell
chloroquin
either
infect
sarscov
could
prevent
infect
treat
infect
cell
suggest
prophylact
therapeut
effect
studi
found
chloroquin
disturb
biochem
matur
cellular
receptor
angiotensin
convert
enzym
sarscov
increas
ph
intracellular
virusladen
vesicl
inhibit
viral
normal
multipl
process
receptor
also
highli
predict
vitro
studi
also
found
chloroquin
hydroxychloroquin
lesstox
deriv
chloroquin
abl
effect
inhibit
viral
growth
found
viral
biolog
process
endosom
affect
antimalari
agent
report
effect
concentr
drug
higher
normal
serum
concentr
report
peopl
take
drug
concentr
lung
vital
organ
higher
common
sideeffect
retinopathi
sideeffect
precipit
due
higher
concentr
compound
blood
recommend
chloroquin
phosphat
dosag
malaria
treatment
adult
gm
oral
follow
mg
hour
first
day
mg
per
day
second
third
day
similarli
dosag
hydroxychloroquin
mg
oral
follow
mg
hour
first
day
mg
per
day
second
third
day
studi
specif
conduct
examin
variou
dosag
chloroquin
hydroxychloroquin
util
previou
clinic
trial
regist
underw
treatment
pneumonia
caus
guidelin
chines
govern
postul
dose
mg
twice
day
day
adult
age
year
weigh
kg
initi
dose
mg
twice
day
first
two
day
mg
per
day
day
adult
weight
less
kg
systemat
search
regist
clinic
trial
carri
figur
prisma
flowchart
list
clinic
trial
regist
china
util
studi
access
readymad
excel
spreadsheet
chines
clinic
trial
registri
th
march
provid
websit
list
clinic
trial
regist
us
govern
clinic
trial
registri
retriev
search
coronaviru
key
word
th
march
trial
filter
base
presenc
word
chloroquin
titl
irrespect
chemic
form
molecul
hydroxychloroquin
trial
carri
alon
combin
antivira
therapi
excel
spreadsheet
file
prepar
base
variou
head
includ
intervent
group
random
statu
sampl
size
etc
univari
statist
use
report
methodolog
trial
th
march
trial
regist
chines
clinic
trial
registri
start
rd
januari
clinic
trial
use
word
chloroquin
titl
five
report
cancel
one
prophylact
studi
one
anoth
could
retriev
eighteen
clinic
trial
chines
registri
use
downstream
analysi
th
march
entri
obtain
search
coronaviru
relat
clinic
trial
us
clinic
trial
registri
regist
januari
registr
relat
use
chloroquin
four
regist
china
brazil
franc
mexico
us
canada
thailand
south
korea
unit
kingdom
norway
turkey
two
studi
us
unit
kingdom
mexico
turkey
prophylact
studi
healthi
peopl
risk
infect
thu
studi
us
trial
registri
use
analysi
total
clinic
trial
regist
sinc
februari
six
prophylact
studi
analyz
separ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
h
c
q
r
g
w
h
f
f
e
r
e
n
n
v
r
l
r
trial
use
oral
chloroquin
hydroxychloroquin
singli
treatment
option
follow
chloroquin
combin
antivir
hydroxychloroquin
azithromycin
chloroquin
aerosol
chloroquin
azithromycin
hydroxychloroquin
antivir
tabl
maximum
quantiti
chloroquin
given
g
period
day
lowest
report
g
aerosol
chloroquin
durat
day
similarli
maximum
quantiti
hydroxychloroquin
given
gm
durat
day
lowest
amount
gm
period
day
one
two
trial
use
aerosol
chloroquin
phosphat
state
dosag
gm
period
day
studi
patient
plan
enrol
trial
twelv
trial
regist
us
registri
nt
detail
sampl
size
alloc
individu
intervent
arm
remain
individu
trial
inform
sampl
size
patient
get
chloroquin
alon
get
hydroxychloroquin
alon
got
chloroquin
drug
get
aerosol
chloroquin
get
convent
treatment
placebo
get
antivir
activ
placebo
intervent
also
get
convent
treatment
standard
care
clinic
trial
report
design
random
two
singl
arm
studi
nt
requir
random
report
use
kind
random
total
threefourth
studi
set
year
old
lower
age
limit
inclus
criteria
two
trial
use
year
one
trial
use
year
similarli
upper
age
limit
rang
year
age
trial
report
enrol
gender
studi
among
trial
use
chloroquin
hydroxychloroquin
prophylact
agent
tabl
healthi
atrisk
popul
enrol
uk
studi
univers
oxford
enrol
individu
durat
three
month
mg
chloroquin
daili
least
dose
plan
given
studi
turkey
mg
hydroxychloroquin
plan
given
everi
three
week
along
daili
vitamin
c
zinc
tablet
result
trial
success
provid
lowcost
option
vaccin
may
requir
year
avail
develop
world
two
trial
china
recent
publish
result
background
inform
chines
clinic
trial
reveal
fifti
percent
efficaci
chloroquin
phosphat
day
medic
compar
efficaci
combinatori
medic
lopinavirritonavir
day
medic
chines
pneumonia
patient
chines
govern
th
th
guidelin
treatment
novel
coronaviru
pneumonia
recommend
use
chloroquin
phosphat
specif
dosag
tabl
three
studi
includ
two
mention
earlier
publish
assess
efficaci
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
hydroxychloroquin
patient
nonrandom
openlabel
clinic
trial
franc
enrol
hospit
patient
hydroxychloroquin
patient
control
arm
patient
conclud
posit
effect
hydroxychloroquin
hydroxychloroquin
plu
azithromycin
base
viral
neg
day
patient
nt
consent
hydroxychloroquin
exclus
criteria
allergi
hydroxychloroquin
retinopathi
defici
qt
prolong
breast
feedingpregnaci
admit
hospit
use
hydroxychloroquin
group
control
arm
six
patient
case
arm
also
receiv
azithromycin
prevent
bacteri
superinfect
though
studi
small
sampl
size
random
nt
carri
intentiontotreat
analysi
conclud
posit
effect
hydroxychloroquin
arm
spite
lesser
proport
asymptomat
patient
hydroxychloroquin
arm
vs
control
arm
higher
averag
age
year
hydroxychloroquin
arm
vs
year
control
arm
intervent
arm
moreov
secondari
analysi
cover
weak
statist
analys
origin
author
found
azithromycin
hydroxychloroquin
combin
better
compar
control
arm
anoth
studi
carri
open
label
random
clinic
trial
chines
patient
treat
either
hydroxychloroquin
patient
convent
method
patient
studi
conclud
appar
benefit
hydroxychloroquin
treatment
compar
convent
treatment
treatment
arm
vs
control
arm
neg
viral
convers
day
p
author
report
use
interferon
alfa
patient
patient
arm
treat
antivir
therapi
moreov
author
caution
high
recoveri
rate
control
arm
due
enrol
mild
case
could
impact
comparison
efficaci
treatment
arm
third
publish
studi
preprint
time
write
manuscript
renmin
hospit
wuhan
univers
wuhan
china
claim
find
posit
effect
hydroxychloroquin
doubleblind
random
control
design
patient
treatment
arm
mg
hydroxychloroquineday
day
improv
pneumonia
compar
control
arm
along
better
outcom
measur
treatment
arm
patient
arm
report
treat
antivir
antibiot
recent
review
found
inclus
chloroquinehydroxychloroquin
base
therapi
nation
guidelin
china
korea
netherland
itali
canada
belgium
recent
us
food
drug
administr
allow
emerg
use
author
drug
use
valid
health
care
provid
modern
robust
scientif
intervent
nation
intern
level
prevent
contain
treatment
protect
mankind
variou
deadli
diseas
like
ebola
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
etc
contemporari
paramet
spanish
flu
one
hundr
year
ago
claim
million
live
modern
scientif
knowledg
contemporarili
lack
limit
predict
absenc
measur
global
popul
infect
forecast
expert
approxim
requir
treatment
chloroquin
phosphat
hydroxychloroquin
sulphat
cost
could
rang
ten
thousand
usd
per
million
popul
tabl
tabl
thu
studi
warrant
confirm
efficaci
safeti
use
medic
spite
continu
effort
tri
differ
dosag
ethic
valid
clinic
trial
requir
assess
effect
safe
dosag
administr
importantli
contribut
guid
medic
profession
prescrib
accur
intervent
also
contribut
pharmaceut
compani
decid
appropri
manufactur
pathway
hydroxchloroquin
low
dosag
requir
lesser
side
effect
compar
price
complet
prescrib
treatment
five
time
chloroquin
phosphat
malaria
endem
poor
part
world
preval
still
less
panic
fear
caus
preval
prompt
pharmaceut
scale
product
chloroquin
chloroquin
signific
advers
event
effect
shortcours
dose
import
moreov
drug
prescrib
week
month
variou
indic
intervent
short
diseas
cours
week
mild
week
sever
critic
case
may
significantli
hamper
treatment
antivir
drug
pipelin
may
use
product
suppli
develop
countri
may
requir
lengthi
timefram
wherea
mass
product
chloroquin
hydroxychloroquin
alreadi
place
malaria
endem
develop
countri
evalu
potenti
favor
benefitrisk
balanc
without
choic
valid
therapeut
option
left
chloroquin
hydroxychloroquin
could
applic
manag
present
context
outbreak
howev
respect
nation
guidelin
clinician
evalu
decis
recommend
conclus
chloroquin
hydroxchloroquin
might
therapeut
potenti
medic
current
context
pandem
situat
howev
corrobor
evid
undergo
clinic
trial
definit
demand
make
ultim
decis
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
